|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, given that studies with incretin receptor antagonists indicate that not all of the glucose-lowering effects of DPP-4 inhibition can be accounted for by GLP-1 alone, evidence supports the notion that GIP may play a role in mediating the anti-hyperglycaemic effects of DPP-4 inhibition, while its glucagonotropic actions at lower glucose levels may contribute to the low risk of hypoglycaemia associated with DPP-4 inhibitors.
|
31706956 |
2020 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adding new oral glucose-lowering drugs to insulin such as DPP-4 inhibitors lead to a modest HbA1c reduction without weight gain and no increase in hypoglycemia.
|
31567175 |
2020 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA<sub>1C</sub> and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
|
30611254 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such compounds may have a place in the treatment of diabetes within the diet; however, while DPP-4 inhibition alone is not associated with hypoglycemia, in combinations with other medication hypoglycemia can result, therefore, it is critical to know what herbal or food-based compounds may have these activities in the management of diabetes patients.
|
30775811 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 (DPP-4) inhibitors play an increasingly important role in the treatment of T2DM because of their favorable properties of weight neutrality and hypoglycemia avoidance.
|
30694668 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, compared to AGIs, DPP4 inhibitors was associated with lower reductions of fasting blood glucose (WMD: -0.53 mmol/L, <i>P</i> < 0.001) and postprandial glucose at 2h (WMD: -0.60 mmol/L, <i>P</i> = 0.04), moderately increased body weight (WMD: 0.34 kg, <i>P</i> = 0.02), and decreased risk of gastrointestinal adverse events [risk ratio (RR): 0.48, <i>P</i> < 0.001], but unaffected risk of symptomatic hypoglycemia (RR: 0.96, <i>P</i> = 0.90).
|
31354492 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.
|
31666589 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems.
|
30901912 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Incretin therapy (DPP-4 inhibitors and GLP-1 receptor agonists) offers an advantage in this respect, because it reduces glucose with a low risk of hypoglycaemia, both in monotherapy and in combination with other therapies.
|
31279738 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monotherapy with DPP-4 inhibitors also had less rates of hypoglycemia (RR: 0·31; 95% CI, 0·24-0·41; p < 0·00001; I<sup>2</sup> = 0%; 8 studies) and severe hypoglycemic events (RR: 0·26; 95% CI, 0·10-0·66; p = 0·004; I<sup>2</sup> = 0%; 8 studies) and patients did not gain 1·19 kg.
|
30710655 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early hypoglycemic medications, especially dipeptidyl peptidase-4 inhibitors with low risks of hypoglycemia, might be prescribed based on patient characteristics.
|
31787718 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, DPP-4 inhibitors have a favorable safety profile and can be used without dose adjustments in older adults and in patients with mild renal impairment; they have a neutral effect on body weight and do not cause hypoglycemia by themselves.
|
30603867 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The DPP-4 inhibitors were also found to have a low risk of adverse events, including hypoglycemia.
|
31275243 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of a DPP-4 inhibitor and exercise, which lowers the risk of hypoglycaemia, is useful for improving insulin resistance by inhibiting excess insulin secretion and decreasing hepatic lipid accumulation, validated by downregulated CD36.
|
31020720 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypoglycemia risk for DPP-4 inhibitors, SGLT2 inhibitors, and thiazolidinediones was generally very low but increased slightly for both GLP-1RAs and metformin.
|
30457671 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Except for hypoglycemia and upper respiratory tract infection (URTI), there are no statistical significance on incidence of adverse events and the body weight when DPP4-I are compared with each other or with placebo.
|
30242726 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DPP-4 inhibitors or "gliptins" are weight neutral, pose lesser risk of hypoglycemia, and provide a long-term post-meal glycemic control.
|
29878387 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the adjusted Cox model, the use of NPH compared to that of DPP-4 inhibitors was associated with a higher risk of discontinuation (HR: 1.33; 95% CI 1.27-1.40) and hypoglycemia (HR: 2.98; 95% CI 2.72-3.28).
|
29713649 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Administering DPP-4 inhibitors within this regimen may contribute to improve patients' glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.
|
28704854 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypoglycemia risk was higher in the patients using insulin (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.16-4.08, P = 0.015), and lower in patients who were being treated with dipeptidyl peptidase-4 inhibitors (OR 0.47, 95% CI: 0.25-0.89, P = 0.019).
|
28397367 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to estimate annual hypoglycemia event rates and costs among patients with type 2 diabetes mellitus (T2DM) who started either SU or dipeptidyl peptidase-4 inhibitors (DPP-4i) and to predict rates and costs in the absence of DPP-4i.
|
30284688 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven RCTs were included.Compared with pioglitazone monotherapy, combination DPP-4 inhibitor and pioglitazone therapy were associated with increased reduction in HbA1c ([MD]-0.64%;-0.73 to -0.55) and FPG ([MD] -0.94; -1.12 to -0.76) levels, more patients in the combination therapy groups versus pioglitazone monotherapy groups had an A1c of < 7% ([OR]2.52; 2.18, 3.17) at the end of the studies, but was not associated with further reduction in higher risk of hypoglycaemia, edema, or any other system AEs.
|
30431561 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with DPP-4 inhibitors combined with insulin improved glycemic control without an increased risk of hypoglycemia or weight gain compared with insulin treatment alone.
|
29047219 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, whether DPP-4 inhibition affects the glucagon response to hypoglycaemia in the elderly is not known and was the aim of this study.
|
29645341 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, no studies have evaluated glucose excursions and the frequency of hypoglycemia in patients treated with mitiglinide/voglibose versus glimepiride as add-on to dipeptidyl peptidase-4 inhibitor therapy.
|
29493100 |
2018 |